Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL

Chimeric antigen receptor (CAR) T cells have emerged as an effective treatment option for patients with relapsed and/or refractory (R/R) diffuse large B cell lymphoma (DLBCL) who are ineligible for autologous stem-cell transplantation (ASCT), although owing to manufacturing and access-related limitations many patients receive rituximab plus gemcitabine–oxaliplatin. Now, data from the phase III STARGLO trial show that addition of the CD20 × CD3 bispecific T cell engager glofitamab to chemotherapy provides an overall survival (OS) benefit over the rituximab regimen in this setting.

Patients were randomly allocated to receive gemcitabine–oxaliplatin plus either glofitamab (n = 183) or rituximab (n = 91). Most patients (63%) had received only one prior line of therapy. OS was the primary end point.